P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL por Mark J Levis, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, Jaime E. Connolly Rohrbach, Ken C.N. Chang, James Hanyok, LI Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Alexander E. Perl

Obter o texto integral